Affinage

ALDH7A1

Alpha-aminoadipic semialdehyde dehydrogenase · UniProt P49419

Length
539 aa
Mass
58.5 kDa
Annotated
2026-06-09
100 papers in source corpus 12 papers cited in narrative 9 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ALDH7A1 (antiquitin) is an NAD+-dependent aldehyde dehydrogenase that operates at the intersection of amino acid catabolism, osmotic and oxidative stress defense, and cellular energy homeostasis (PMID:20207735). It catalyzes the oxidation of α-aminoadipic semialdehyde (α-AASA) — the critical step in brain lysine degradation that produces α-aminoadipic acid — as well as betaine aldehyde (generating the osmolyte betaine) and lipid peroxidation-derived aldehydes such as 4-HNE, and its expression protects cells from osmotic and aldehyde/oxidant cytotoxicity (PMID:20207735, PMID:21338592). Loss-of-function mutations in ALDH7A1 cause pyridoxine-dependent epilepsy: impaired α-AASA dehydrogenation allows accumulation of piperideine-6-carboxylate (P6C), which inactivates pyridoxal 5'-phosphate by Knoevenagel condensation, producing secondary vitamin B6 deficiency and seizures (PMID:17068770, PMID:20554659, PMID:19128417, PMID:27856333). This disease mechanism is recapitulated in Aldh7a1-null zebrafish, which show recurrent seizures, PDE biomarker accumulation, reduced GABA, and rescue by pyridoxine/PLP (PMID:29061647, PMID:29053735). Beyond aldehyde clearance, the NADH product of ALDH7A1 acts as a signaling/metabolic output: it inhibits BARS-dependent COPI vesicle fission to suppress intracellular transport and conserve energy during hypoxia and starvation (PMID:31492851), and it supports FSP1-mediated suppression of ferroptosis on cellular membranes, with AMPK-driven membrane recruitment of ALDH7A1 stabilizing FSP1 under ferroptotic stress (PMID:40233740).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 1997 Medium

    Established that antiquitin/ALDH7A1 is a tissue-specifically expressed gene and mapped it to a defined chromosomal locus, providing the molecular handle for later functional and disease work.

    Evidence Northern blot of human fetal tissues, RT-PCR of cochlear hair cell cDNA, FISH and SSCP chromosomal mapping

    PMID:9417906

    Open questions at the time
    • No enzymatic activity or substrate assigned at this stage
    • Functional role in any tissue undefined
  2. 2007 High

    Resolved why ALDH7A1 mutations cause disease, linking loss of α-AASA dehydrogenase activity to PLP inactivation and seizures rather than a vague metabolic defect.

    Evidence Mutational analysis in 18 patients with biochemical measurement of pipecolic acid and α-AASA and clinical correlation

    PMID:17068770 PMID:19128417 PMID:20554659

    Open questions at the time
    • P6C–PLP Knoevenagel condensation inferred biochemically rather than structurally resolved in vivo
    • Did not define the enzyme's full substrate repertoire
  3. 2010 High

    Defined the enzyme's biochemical identity and substrate breadth, showing ALDH7A1 oxidizes α-AASA, betaine aldehyde, and lipid-peroxidation aldehydes and links to osmotic stress protection.

    Evidence Recombinant enzyme assays, crystal structure, stable CHO expression with viability assays, and subcellular fractionation

    PMID:20207735

    Open questions at the time
    • Physiological relevance of multi-organelle (cytosol/nucleus/mitochondria) localization not dissected
    • Relative in vivo flux through each substrate unquantified
  4. 2011 Medium

    Demonstrated a cytoprotective antioxidant role, showing mitochondrial ALDH7A1 detoxifies reactive aldehydes and is itself redox-regulated through oxidative inactivation/reactivation.

    Evidence Stable CHO transfection viability assays and in vitro enzyme assays with oxidant treatment and β-mercaptoethanol rescue

    PMID:21338592

    Open questions at the time
    • Single-lab cell model; in vivo antioxidant contribution not established
    • Physiological redox switch mechanism not defined
  5. 2014 Medium

    Implicated ALDH7A1 in eye/skeletal development beyond metabolism, placing nlz1 functionally downstream in optic cup proliferation.

    Evidence Morpholino knockdown in zebrafish with phenotypic scoring, proliferation assays, and nlz1 mRNA rescue

    PMID:25004007

    Open questions at the time
    • Morpholino-based; not confirmed by stable genetic knockout
    • Molecular link between ALDH7A1 enzymatic activity and nlz1 regulation unknown
  6. 2017 High

    Provided an in vivo genetic model confirming the lysine-catabolism/B6-deficiency seizure mechanism and demonstrating pharmacological rescue.

    Evidence CRISPR-Cas9 knockout zebrafish with EEG, LC-MS/MS metabolite quantification, behavioral assays, and pyridoxine/PLP rescue; replicated by an independent CRISPR study

    PMID:29053735 PMID:29061647

    Open questions at the time
    • Does not address non-metabolic ALDH7A1 functions
    • Mechanism of GABA reduction downstream of PLP deficiency not fully traced
  7. 2019 High

    Revealed a signaling role for the enzyme's NADH product, connecting ALDH7A1 activity to suppression of COPI vesicle fission and energy conservation under nutrient/oxygen limitation.

    Evidence COPI vesicle formation assays, NADH measurement, BARS interaction studies, and genetic manipulation with energy-consumption readouts under hypoxia/starvation

    PMID:31492851

    Open questions at the time
    • Direct structural basis of NADH–BARS regulation not resolved
    • Tissue/physiological contexts where this pathway dominates unclear
  8. 2025 High

    Extended the NADH-output paradigm to ferroptosis defense, showing AMPK-driven membrane recruitment of ALDH7A1 supports and stabilizes FSP1 while direct aldehyde clearance lowers lipid peroxidation.

    Evidence NADH localization and FSP1 activity assays, AMPK activation/inhibition, membrane fractionation, and ALDH7A1 perturbation with ferroptosis/lipid peroxidation readouts

    PMID:40233740

    Open questions at the time
    • Mechanism of AMPK-dependent membrane targeting of ALDH7A1 not molecularly defined
    • Relative contribution of NADH-FSP1 axis versus direct aldehyde consumption not quantified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ALDH7A1's distinct activities — lysine catabolism, osmolyte/aldehyde detoxification, NADH-driven COPI inhibition, and ferroptosis suppression — are coordinated and partitioned across its cytosolic, nuclear, mitochondrial, and membrane pools remains unresolved.
  • No integrated model linking subcellular localization to specific functional output
  • Whether the developmental (coloboma) phenotype reflects metabolic or NADH-signaling functions is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016491 oxidoreductase activity 4 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005739 mitochondrion 2 GO:0005634 nucleus 1 GO:0005829 cytosol 1 GO:0005886 plasma membrane 1
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-8953897 Cellular responses to stimuli 3 R-HSA-5357801 Programmed Cell Death 1 R-HSA-5653656 Vesicle-mediated transport 1
Partners
BARSFSP1

Evidence

Reading pass · 9 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 Human ALDH7A1 (antiquitin) catalyzes the NAD+-dependent dehydrogenation of α-aminoadipic semialdehyde (α-AASA), betaine aldehyde (generating the osmolyte betaine), and lipid peroxidation-derived aldehydes (including 4-HNE). Expression of ALDH7A1 in CHO cells attenuated osmotic stress-induced apoptosis. The crystal structure supports these substrate specificities. ALDH7A1 protein was found in the cytosol, nucleus, and mitochondria, with mitochondrial and cytosolic transcripts differentially expressed in a tissue-specific manner in mice. Recombinant protein enzyme activity assays, crystal structure determination, stable CHO cell expression with viability assays, tissue fractionation/Western blot, cDNA sequence analysis The Journal of biological chemistry High 20207735
2007 Mutations in ALDH7A1 (antiquitin) cause pyridoxine-dependent epilepsy (PDE) by impairing α-AASA dehydrogenase activity in the cerebral lysine degradation pathway. The accumulating intermediate piperideine-6-carboxylate (P6C) inactivates pyridoxal phosphate (PLP) via Knoevenagel condensation, leading to secondary PLP deficiency and seizures. Elevated pipecolic acid and α-AASA in plasma/urine/CSF serve as biomarkers. Mutational analysis of ALDH7A1 in 18 patients, biochemical measurement of plasma PA and α-AASA, clinical correlation Human mutation High 17068770 19128417 20554659
2011 Stable expression of mitochondrial ALDH7A1 in CHO cells provides significant protection against lipid peroxidation-derived aldehydes (hexanal and 4-HNE) and hydrogen peroxide cytotoxicity. In vitro enzyme assays show ALDH7A1 is sensitive to oxidative inactivation and can be reactivated by the reducing agent β-mercaptoethanol; reactivated ALDH7A1 metabolizes 4-HNE directly. Stable CHO cell transfection with viability assays, in vitro recombinant enzyme activity assays with oxidant treatment and β-mercaptoethanol rescue Chemico-biological interactions Medium 21338592
2019 ALDH7A1 enzymatic activity generates NADH from NAD+; this NADH product targets BARS (Brefeldin-A ADP-Ribosylated Substrate) to inhibit COPI vesicle fission, thereby broadly inhibiting intracellular transport pathways. During hypoxia and starvation, this transport inhibition reduces energy consumption to promote cellular energy homeostasis. Biochemical assays of COPI vesicle formation, NADH measurement, BARS interaction studies, knockdown/overexpression experiments, energy consumption assays under hypoxia/starvation Nature communications High 31492851
2025 ALDH7A1 protects against ferroptosis through two mechanisms: (1) its dehydrogenase activity generates NADH on cellular membranes, which supports FSP1 (ferroptosis suppressor protein 1) activity to reduce lipid peroxidation; (2) it directly consumes reactive aldehydes to decrease lipid peroxidation. Under ferroptotic stress, AMPK is activated and promotes membrane localization of ALDH7A1, which in turn stabilizes FSP1 on membranes. NADH localization assays, FSP1 activity assays, AMPK activation/inhibition experiments, membrane fractionation, ALDH7A1 knockdown/overexpression with ferroptosis readouts, lipid peroxidation assays Cell High 40233740
2017 Aldh7a1-null zebrafish (generated by CRISPR-Cas9) display spontaneous recurrent seizures with epileptiform electrographic activity, impaired lysine degradation with accumulation of PDE biomarkers (α-AASA, P6C, pipecolic acid), B6 deficiency, and reduced GABA levels. Seizures are rescued by pyridoxine/pyridoxal 5'-phosphate, and lysine supplementation aggravates the phenotype. CRISPR-Cas9 knockout zebrafish, electroencephalography (tectal recordings), LC-MS/MS metabolite quantification, behavioral assays, pharmacological rescue experiments Genetics High 29053735 29061647
1997 Human antiquitin (ATQ1/ALDH7A1) is expressed in cochlear outer hair cells (detected by RT-PCR of rat hair cell-specific cDNA), as well as highly in human fetal cochlea, ovary, eye, heart, and kidney. The gene was mapped to human chromosome 5q31 by FISH and mouse chromosome 18 by SSCP mapping. Northern blot of 13 human fetal tissues, RT-PCR of rat cochlear hair cell-specific cDNA libraries, FISH, SSCP mapping Genomics Medium 9417906
2014 Morpholino knockdown of aldh7a1 in zebrafish causes uveal coloboma and skeletal abnormalities, with reduced cell proliferation in the optic cup. The coloboma phenotype is associated with misregulation of nlz1 (a known coloboma gene), and is partially rescued by co-injection of nlz1 mRNA, placing nlz1 functionally downstream of aldh7a1 in regulating optic cup cell proliferation. Morpholino knockdown in zebrafish, phenotypic scoring, cell proliferation assays, gene expression analysis, mRNA rescue experiments PloS one Medium 25004007
2016 ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase (antiquitin), which converts α-aminoadipic semialdehyde (α-AASA) into α-aminoadipic acid (AAA) as a critical step in brain lysine catabolism. ALDH7A1 dysfunction causes accumulation of α-AASA and P6C; P6C binds and inactivates PLP (the active form of vitamin B6). A novel missense mutation (c.566G>A, p.Gly189Glu) in the NAD+ binding domain of exon 6 was shown to cause neonatal PDE. Sequence analysis, clinical biochemistry, mutation characterization Molecular and cellular probes Medium 27856333

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacology & therapeutics 702 16102838
2012 Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. British journal of pharmacology 308 22014080
1997 Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends in pharmacological sciences 233 9184477
2002 The complex of Arl2-GTP and PDE delta: from structure to function. The EMBO journal 192 11980706
2010 Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain : a journal of neurology 190 20554659
2004 Potency, selectivity, and consequences of nonselectivity of PDE inhibition. International journal of impotence research 184 15224129
2003 L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric oxide : biology and chemistry 173 14996430
2010 Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. The Journal of biological chemistry 162 20207735
2012 Selective PDE inhibitors as novel treatments for respiratory diseases. Current opinion in pharmacology 123 22497841
2012 EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era. Nucleic acids research 123 23193273
2009 Global and gene-specific promoter methylation changes are related to anti-B[a]PDE-DNA adduct levels and influence micronuclei levels in polycyclic aromatic hydrocarbon-exposed individuals. International journal of cancer 119 19521983
2007 Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Human mutation 117 17068770
1995 Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Molecular pharmacology 117 7476886
1995 PDE isoenzymes as targets for anti-asthma drugs. The European respiratory journal 114 7589403
2006 Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. European urology 108 16460876
2013 Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. Journal of pharmaceutical and biomedical analysis 102 23721687
2018 A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular oncology 99 30117261
2020 EPD in 2020: enhanced data visualization and extension to ncRNA promoters. Nucleic acids research 85 31680159
2019 The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy. Journal of inherited metabolic disease 82 30043187
2006 Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. European urology 82 16815627
1994 Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. The Biochemical journal 81 7998974
2001 Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney international 78 11380813
2017 Pyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency. Genetics 76 29061647
2011 Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chemico-biological interactions 76 21338592
2007 PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia? Drug discovery today 75 17933689
2008 Prevalence of ALDH7A1 mutations in 18 North American pyridoxine-dependent seizure (PDS) patients. Epilepsia 64 19128417
2004 The Eukaryotic Promoter Database EPD: the impact of in silico primer extension. Nucleic acids research 62 14681364
2010 Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Current pharmaceutical design 59 20030615
2007 Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Experimental biology and medicine (Maywood, N.J.) 59 17202584
2015 PHLPP2 Downregulation Contributes to Lung Carcinogenesis Following B[a]P/B[a]PDE Exposure. Clinical cancer research : an official journal of the American Association for Cancer Research 58 25977341
2018 PDE/cAMP/Epac/C/EBP-β Signaling Cascade Regulates Mitochondria Biogenesis of Tubular Epithelial Cells in Renal Fibrosis. Antioxidants & redox signaling 53 29216750
2015 PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. The Journal of neuroscience : the official journal of the Society for Neuroscience 51 25568131
2001 Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular drug reviews 51 11607039
2015 Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulmonary pharmacology & therapeutics 49 25899618
2022 Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence. Molecules (Basel, Switzerland) 46 36500540
2014 PDE and cognitive processing: beyond the memory domain. Neurobiology of learning and memory 45 25464010
2010 Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database. Journal of biomolecular structure & dynamics 45 20085380
2002 Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Molecular pharmacology 45 12181425
2002 AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors. American journal of physiology. Renal physiology 43 12388409
2002 PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annual review of sex research 42 12836729
1991 Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents and actions. Supplements 42 1665311
1996 Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood 40 8695850
2003 Prolactin, progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 beta-cells. American journal of physiology. Endocrinology and metabolism 39 14559722
2006 Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. European journal of pharmacology 38 16956605
1995 Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]. The Biochemical journal 38 7772058
2025 ALDH7A1 protects against ferroptosis by generating membrane NADH and regulating FSP1. Cell 35 40233740
2017 Atrazine suppresses FSH-induced steroidogenesis and LH-dependent expression of ovulatory genes through PDE-cAMP signaling pathway in human cumulus granulosa cells. Molecular and cellular endocrinology 35 28859905
1993 The role of the cyclic nucleotide phosphodiesterase of Dictyostelium discoideum during growth, aggregation, and morphogenesis: overexpression and localization studies with the separate promoters of the pde. Developmental biology 35 8387036
2007 Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Molecular genetics and metabolism 34 17433748
2007 Treating COPD with PDE 4 inhibitors. International journal of chronic obstructive pulmonary disease 34 18268925
1997 An ancient conserved gene expressed in the human inner ear: identification, expression analysis, and chromosomal mapping of human and mouse antiquitin (ATQ1). Genomics 34 9417906
2019 Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology. PLoS computational biology 33 31206508
2017 Characterization of the first knock-out aldh7a1 zebrafish model for pyridoxine-dependent epilepsy using CRISPR-Cas9 technology. PloS one 32 29053735
2008 PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 31 18596129
2007 Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKKbeta/NF-kappaB in mouse epidermal Cl41 cells. Molecular carcinogenesis 31 16921490
2021 The PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family. Trends in genetics : TIG 30 33832760
2017 Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. British journal of pharmacology 30 28548283
2017 PDE Inhibitors for the Treatment of Schizophrenia. Advances in neurobiology 30 28956340
2014 Active site coupling in PDE:PKA complexes promotes resetting of mammalian cAMP signaling. Biophysical journal 30 25229150
2006 Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulmonary pharmacology & therapeutics 30 16427796
2013 Rutin inhibits B[a]PDE-induced cyclooxygenase-2 expression by targeting EGFR kinase activity. Biochemical pharmacology 29 24021351
2017 Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells. Proceedings of the National Academy of Sciences of the United States of America 28 28634298
2014 An EPD/WSD motifs containing C-type lectin from Argopectens irradians recognizes and binds microbes with broad spectrum. Fish & shellfish immunology 28 25555809
2019 ALDH7A1 inhibits the intracellular transport pathways during hypoxia and starvation to promote cellular energy homeostasis. Nature communications 27 31492851
2013 ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Future oncology (London, England) 27 23647301
2011 PDE inhibitors: a new approach to treat metabolic syndrome? Current opinion in pharmacology 27 22018840
2010 Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 27 20382846
2015 Intragenic deletions of ALDH7A1 in pyridoxine-dependent epilepsy caused by Alu-Alu recombination. Neurology 24 26224730
2014 Clinical diagnosis, treatment, and ALDH7A1 mutations in pyridoxine-dependent epilepsy in three Chinese infants. PloS one 24 24664145
1998 Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. Cell biochemistry and biophysics 24 9515164
2021 PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity. Theranostics 23 33500712
2018 Brain malformations associated to Aldh7a1 gene mutations: Report of a novel homozygous mutation and literature review. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 23 30005813
1996 Characterization of DNA polymorphisms in three populations of hereford cattle and their associations with growth and maternal EPD in line 1 herefords. Journal of animal science 23 8856432
2022 Baicalin attenuates amyloid β oligomers induced memory deficits and mitochondria fragmentation through regulation of PDE-PKA-Drp1 signalling. Psychopharmacology 21 35103832
2015 Parallel Allostery by cAMP and PDE Coordinates Activation and Termination Phases in cAMP Signaling. Biophysical journal 20 26276689
2014 aldh7a1 regulates eye and limb development in zebrafish. PloS one 20 25004007
2001 Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries. British journal of pharmacology 20 11156556
1998 Compartmentalization of PDE-4 and cAMP-dependent protein kinase in neutrophils and macrophages during phagocytosis. Cell biochemistry and biophysics 20 9515168
2023 Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis. Frontiers in pharmacology 19 36865908
2016 A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1. Pediatric neurology 19 27212567
1999 Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. Biochemical pharmacology 19 10509746
2023 cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. Biochemistry and biophysics reports 18 36865738
2021 Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line. Molecular and cellular endocrinology 18 34875337
2024 Parameter Identifiability in PDE Models of Fluorescence Recovery After Photobleaching. Bulletin of mathematical biology 17 38430382
2023 Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport. Journal of ethnopharmacology 17 38158096
2022 A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice. Journal of personalized medicine 17 35629230
2020 A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury. Current neuropharmacology 17 31660837
2020 In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels. Molecules (Basel, Switzerland) 17 32102361
2020 Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 β and pCREB expression. Experimental gerontology 17 32791334
2013 The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Current urology reports 17 24136683
2011 Cyanidin-3-glucoside suppresses B[a]PDE-induced cyclooxygenase-2 expression by directly inhibiting Fyn kinase activity. Biochemical pharmacology 16 21501596
2004 Unraveling genes and pathways influenced by H-prune PDE overexpression: a model to study cellular motility. Cell cycle (Georgetown, Tex.) 16 15254413
2023 Unleashing Spinal Cord Repair: The Role of cAMP-Specific PDE Inhibition in Attenuating Neuroinflammation and Boosting Regeneration after Traumatic Spinal Cord Injury. International journal of molecular sciences 15 37175842
2021 H2 S catalysed by CBS regulates testosterone synthesis through affecting the sulfhydrylation of PDE. Journal of cellular and molecular medicine 15 33713531
2015 Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells. Journal of experimental & clinical cancer research : CR 15 25907439
2013 Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of the ALDH7A1 gene. Gene 15 23376216
2013 Tehranolide inhibits cell proliferation via calmodulin inhibition, PDE, and PKA activation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 15 24222327
1998 Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3). Cell biochemistry and biophysics 15 9631240
2016 Novel homozygous missense mutation in ALDH7A1 causes neonatal pyridoxine dependent epilepsy. Molecular and cellular probes 14 27856333
1998 Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. Cell biochemistry and biophysics 14 9631239

Missed literature

Know a paper Affinage missed for ALDH7A1? Flag it for the maintainers and the community.

No submissions yet.